CGON
Price
$25.86
Change
-$0.64 (-2.42%)
Updated
Jun 13 closing price
Capitalization
1.97B
54 days until earnings call
EXEL
Price
$41.59
Change
-$0.19 (-0.45%)
Updated
Jun 13 closing price
Capitalization
11.34B
59 days until earnings call
Interact to see
Advertisement

CGON vs EXEL

Header iconCGON vs EXEL Comparison
Open Charts CGON vs EXELBanner chart's image
CG Oncology
Price$25.86
Change-$0.64 (-2.42%)
Volume$626.38K
Capitalization1.97B
Exelixis
Price$41.59
Change-$0.19 (-0.45%)
Volume$2.13M
Capitalization11.34B
CGON vs EXEL Comparison Chart
Loading...
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGON vs. EXEL commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a Hold and EXEL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (CGON: $25.86 vs. EXEL: $41.59)
Brand notoriety: CGON: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 43% vs. EXEL: 70%
Market capitalization -- CGON: $1.97B vs. EXEL: $11.34B
CGON [@Biotechnology] is valued at $1.97B. EXEL’s [@Biotechnology] market capitalization is $11.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 0 FA rating(s) are green whileEXEL’s FA Score has 2 green FA rating(s).

  • CGON’s FA Score: 0 green, 5 red.
  • EXEL’s FA Score: 2 green, 3 red.
According to our system of comparison, EXEL is a better buy in the long-term than CGON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 3 TA indicator(s) are bullish while EXEL’s TA Score has 4 bullish TA indicator(s).

  • CGON’s TA Score: 3 bullish, 3 bearish.
  • EXEL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CGON and EXEL are a good buy in the short-term.

Price Growth

CGON (@Biotechnology) experienced а -3.90% price change this week, while EXEL (@Biotechnology) price change was -3.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

CGON is expected to report earnings on Aug 07, 2025.

EXEL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($11.3B) has a higher market cap than CGON($1.97B). EXEL YTD gains are higher at: 24.895 vs. CGON (-9.833). EXEL has higher annual earnings (EBITDA): 844M vs. CGON (-134.35M). EXEL has more cash in the bank: 1.03B vs. CGON (688M). CGON has less debt than EXEL: CGON (1.04M) vs EXEL (187M). EXEL has higher revenues than CGON: EXEL (2.3B) vs CGON (662K).
CGONEXELCGON / EXEL
Capitalization1.97B11.3B17%
EBITDA-134.35M844M-16%
Gain YTD-9.83324.895-39%
P/E RatioN/A18.99-
Revenue662K2.3B0%
Total Cash688M1.03B67%
Total Debt1.04M187M1%
FUNDAMENTALS RATINGS
EXEL: Fundamental Ratings
EXEL
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
31
SMR RATING
1..100
32
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGONEXEL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 5 days ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 24 days ago
87%
Bearish Trend 4 days ago
62%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
56%
View a ticker or compare two or three
Interact to see
Advertisement
CGON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIJCX86.12N/A
N/A
Fidelity Advisor Consumer Staples Z
RAMHX35.46-0.30
-0.84%
American Funds American Balanced R2E
LSIFX143.31-2.11
-1.45%
ClearBridge Growth IS
TPCIX25.96-0.40
-1.52%
Timothy Plan Israel Common Values C
AEDAX35.88-0.64
-1.75%
Invesco EQV European Equity A

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
-2.42%
IDYA - CGON
60%
Loosely correlated
-0.45%
ACLX - CGON
56%
Loosely correlated
-0.77%
SYRE - CGON
56%
Loosely correlated
-2.37%
KYMR - CGON
54%
Loosely correlated
-0.70%
XNCR - CGON
54%
Loosely correlated
-2.55%
More

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and RIGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and RIGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-0.45%
RIGL - EXEL
29%
Poorly correlated
-3.66%
RVMD - EXEL
28%
Poorly correlated
-1.26%
ACLX - EXEL
28%
Poorly correlated
-0.77%
UTHR - EXEL
28%
Poorly correlated
-0.98%
CGON - EXEL
28%
Poorly correlated
-2.42%
More